Virginia Borges
Concepts (598)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 153 | 2026 | 2418 | 12.770 |
Why?
| | Pregnancy Complications, Neoplastic | 18 | 2026 | 64 | 3.730 |
Why?
| | Postpartum Period | 21 | 2026 | 377 | 2.820 |
Why?
| | Cancer Survivors | 20 | 2025 | 348 | 2.390 |
Why?
| | Receptors, Estrogen | 24 | 2026 | 406 | 2.240 |
Why?
| | Antineoplastic Agents, Hormonal | 16 | 2026 | 196 | 2.090 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 22 | 2026 | 1998 | 1.970 |
Why?
| | Carcinoma, Ductal, Breast | 10 | 2023 | 92 | 1.670 |
Why?
| | Mastectomy | 17 | 2024 | 189 | 1.550 |
Why?
| | Protein Kinase Inhibitors | 7 | 2025 | 983 | 1.390 |
Why?
| | Receptors, Progesterone | 10 | 2026 | 242 | 1.240 |
Why?
| | Lactation | 9 | 2021 | 193 | 1.220 |
Why?
| | Brain Neoplasms | 11 | 2025 | 1325 | 1.200 |
Why?
| | Female | 172 | 2026 | 79499 | 1.190 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 7 | 2023 | 61 | 1.090 |
Why?
| | Neoplasm Metastasis | 13 | 2025 | 693 | 1.040 |
Why?
| | Adult | 106 | 2026 | 41087 | 1.020 |
Why?
| | Breast | 10 | 2021 | 155 | 0.990 |
Why?
| | Triple Negative Breast Neoplasms | 8 | 2026 | 220 | 0.980 |
Why?
| | Trastuzumab | 14 | 2026 | 119 | 0.930 |
Why?
| | Pregnancy | 38 | 2026 | 7230 | 0.930 |
Why?
| | Oxazoles | 8 | 2025 | 48 | 0.930 |
Why?
| | Antineoplastic Agents | 12 | 2023 | 2219 | 0.900 |
Why?
| | Humans | 181 | 2026 | 146342 | 0.890 |
Why?
| | Pyridines | 9 | 2025 | 610 | 0.840 |
Why?
| | Neoplasm Recurrence, Local | 16 | 2026 | 1160 | 0.830 |
Why?
| | Quinazolines | 8 | 2025 | 267 | 0.830 |
Why?
| | Mammary Glands, Human | 7 | 2020 | 71 | 0.820 |
Why?
| | Supreme Court Decisions | 1 | 2022 | 12 | 0.740 |
Why?
| | Mammary Glands, Animal | 9 | 2021 | 124 | 0.690 |
Why?
| | Carcinoma | 3 | 2021 | 225 | 0.670 |
Why?
| | Neoplasm Staging | 21 | 2026 | 1488 | 0.670 |
Why?
| | BRCA2 Protein | 5 | 2024 | 69 | 0.670 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 1 | 2020 | 34 | 0.650 |
Why?
| | Semaphorins | 4 | 2025 | 37 | 0.640 |
Why?
| | Fertility Preservation | 7 | 2025 | 57 | 0.640 |
Why?
| | Middle Aged | 62 | 2026 | 36619 | 0.630 |
Why?
| | Prospective Studies | 35 | 2026 | 8123 | 0.620 |
Why?
| | Neoadjuvant Therapy | 7 | 2026 | 475 | 0.620 |
Why?
| | Prognosis | 18 | 2026 | 4351 | 0.620 |
Why?
| | Breast Feeding | 6 | 2025 | 447 | 0.600 |
Why?
| | Maternal Age | 1 | 2020 | 129 | 0.600 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2022 | 893 | 0.590 |
Why?
| | Parity | 8 | 2026 | 113 | 0.580 |
Why?
| | Antigens, CD | 6 | 2025 | 560 | 0.580 |
Why?
| | Chemotherapy, Adjuvant | 16 | 2026 | 429 | 0.580 |
Why?
| | Young Adult | 40 | 2026 | 14330 | 0.570 |
Why?
| | Estradiol | 5 | 2019 | 517 | 0.560 |
Why?
| | Biomarkers, Tumor | 13 | 2026 | 1339 | 0.550 |
Why?
| | Extracellular Vesicles | 1 | 2020 | 176 | 0.530 |
Why?
| | Carcinoma in Situ | 3 | 2022 | 45 | 0.530 |
Why?
| | Disease-Free Survival | 11 | 2026 | 778 | 0.520 |
Why?
| | Lymphatic Metastasis | 10 | 2021 | 335 | 0.510 |
Why?
| | Neoplasms, Second Primary | 3 | 2024 | 103 | 0.490 |
Why?
| | Quality of Life | 12 | 2025 | 3200 | 0.480 |
Why?
| | Cyclooxygenase 2 | 5 | 2020 | 166 | 0.460 |
Why?
| | Mutation | 11 | 2025 | 4093 | 0.420 |
Why?
| | Capecitabine | 5 | 2023 | 56 | 0.420 |
Why?
| | Melanoma | 4 | 2018 | 765 | 0.410 |
Why?
| | Skin Neoplasms | 4 | 2013 | 806 | 0.410 |
Why?
| | Aromatase Inhibitors | 6 | 2019 | 81 | 0.410 |
Why?
| | Liver Neoplasms | 4 | 2016 | 776 | 0.410 |
Why?
| | Carcinoma, Lobular | 2 | 2012 | 59 | 0.400 |
Why?
| | Mastectomy, Segmental | 6 | 2022 | 107 | 0.400 |
Why?
| | Combined Modality Therapy | 10 | 2023 | 1271 | 0.390 |
Why?
| | Puerperal Disorders | 2 | 2014 | 35 | 0.390 |
Why?
| | BRCA1 Protein | 4 | 2024 | 84 | 0.380 |
Why?
| | Stromal Cells | 3 | 2013 | 123 | 0.360 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2021 | 530 | 0.350 |
Why?
| | Genes, BRCA2 | 3 | 2026 | 33 | 0.340 |
Why?
| | Genes, BRCA1 | 3 | 2026 | 45 | 0.340 |
Why?
| | Anxiety | 7 | 2022 | 1125 | 0.340 |
Why?
| | Resistance Training | 2 | 2025 | 186 | 0.330 |
Why?
| | Neoplasms | 7 | 2026 | 2954 | 0.330 |
Why?
| | Nevus, Pigmented | 1 | 2011 | 35 | 0.330 |
Why?
| | Antibodies, Monoclonal, Humanized | 8 | 2026 | 992 | 0.330 |
Why?
| | Sexual Partners | 3 | 2022 | 195 | 0.330 |
Why?
| | Epithelial Cells | 6 | 2018 | 1119 | 0.320 |
Why?
| | Neoplasm Invasiveness | 6 | 2020 | 504 | 0.320 |
Why?
| | Aged | 31 | 2026 | 26432 | 0.310 |
Why?
| | Social Support | 4 | 2025 | 646 | 0.310 |
Why?
| | Fertility | 5 | 2025 | 174 | 0.310 |
Why?
| | Cohort Studies | 13 | 2026 | 6077 | 0.310 |
Why?
| | Tamoxifen | 7 | 2021 | 193 | 0.310 |
Why?
| | Premenopause | 6 | 2026 | 130 | 0.300 |
Why?
| | Estrogens | 4 | 2015 | 364 | 0.300 |
Why?
| | Cyclophosphamide | 5 | 2020 | 275 | 0.290 |
Why?
| | Radiosurgery | 3 | 2021 | 398 | 0.290 |
Why?
| | Adjuvants, Immunologic | 2 | 2022 | 245 | 0.290 |
Why?
| | Gene Expression Profiling | 8 | 2020 | 1792 | 0.290 |
Why?
| | Thrombophilia | 1 | 2009 | 89 | 0.280 |
Why?
| | Risk Factors | 17 | 2024 | 10921 | 0.280 |
Why?
| | T-Lymphocytes | 6 | 2018 | 2012 | 0.280 |
Why?
| | Patient Acceptance of Health Care | 2 | 2025 | 881 | 0.280 |
Why?
| | GPI-Linked Proteins | 4 | 2025 | 81 | 0.280 |
Why?
| | Incidence | 7 | 2024 | 2936 | 0.270 |
Why?
| | Cell Line, Tumor | 10 | 2025 | 3545 | 0.270 |
Why?
| | Quinolines | 3 | 2025 | 191 | 0.270 |
Why?
| | Mice | 21 | 2025 | 18297 | 0.270 |
Why?
| | Heterozygote | 2 | 2026 | 311 | 0.270 |
Why?
| | Animals | 31 | 2025 | 38107 | 0.260 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2021 | 1432 | 0.260 |
Why?
| | Breast Neoplasms, Male | 2 | 2018 | 29 | 0.260 |
Why?
| | Doxorubicin | 5 | 2020 | 416 | 0.260 |
Why?
| | Follow-Up Studies | 7 | 2026 | 5439 | 0.260 |
Why?
| | Employment | 2 | 2019 | 180 | 0.260 |
Why?
| | Kaplan-Meier Estimate | 4 | 2020 | 970 | 0.260 |
Why?
| | Appetite | 2 | 2025 | 80 | 0.260 |
Why?
| | Decision Making | 4 | 2022 | 993 | 0.250 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2026 | 156 | 0.250 |
Why?
| | Maytansine | 2 | 2018 | 18 | 0.240 |
Why?
| | Myeloid-Derived Suppressor Cells | 2 | 2018 | 78 | 0.240 |
Why?
| | Estrogen Receptor alpha | 3 | 2025 | 154 | 0.240 |
Why?
| | Time Factors | 7 | 2020 | 7109 | 0.230 |
Why?
| | Adaptation, Psychological | 2 | 2022 | 721 | 0.230 |
Why?
| | Delayed Diagnosis | 1 | 2026 | 102 | 0.230 |
Why?
| | Disease Management | 3 | 2021 | 651 | 0.230 |
Why?
| | Estrogen Receptor Antagonists | 1 | 2025 | 4 | 0.230 |
Why?
| | Reproductive History | 2 | 2015 | 12 | 0.220 |
Why?
| | Ovarian Reserve | 1 | 2025 | 19 | 0.220 |
Why?
| | CD8-Positive T-Lymphocytes | 5 | 2023 | 931 | 0.220 |
Why?
| | Germ-Line Mutation | 1 | 2026 | 180 | 0.220 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2025 | 40 | 0.220 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2011 | 704 | 0.220 |
Why?
| | Energy Intake | 2 | 2025 | 507 | 0.220 |
Why?
| | Dimethyl Sulfoxide | 1 | 2005 | 42 | 0.220 |
Why?
| | Mammography | 3 | 2025 | 175 | 0.220 |
Why?
| | Cell Plasticity | 1 | 2025 | 37 | 0.210 |
Why?
| | Macrophages | 4 | 2018 | 1532 | 0.210 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 2 | 2022 | 111 | 0.210 |
Why?
| | Proportional Hazards Models | 2 | 2022 | 1331 | 0.210 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2025 | 176 | 0.210 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2005 | 175 | 0.210 |
Why?
| | Adolescent | 20 | 2024 | 22557 | 0.200 |
Why?
| | Genetic Predisposition to Disease | 6 | 2024 | 2488 | 0.200 |
Why?
| | Time-to-Treatment | 1 | 2026 | 257 | 0.200 |
Why?
| | Bupropion | 1 | 2004 | 47 | 0.200 |
Why?
| | Disease Progression | 10 | 2020 | 2867 | 0.200 |
Why?
| | Reproductive Techniques, Assisted | 1 | 2024 | 48 | 0.200 |
Why?
| | Lymph Nodes | 3 | 2019 | 511 | 0.200 |
Why?
| | Treatment Outcome | 10 | 2026 | 11821 | 0.200 |
Why?
| | Drug Administration Schedule | 3 | 2018 | 790 | 0.200 |
Why?
| | Tumor Microenvironment | 7 | 2026 | 747 | 0.190 |
Why?
| | Diarrhea | 3 | 2019 | 190 | 0.190 |
Why?
| | Multiple Sclerosis | 1 | 2008 | 435 | 0.190 |
Why?
| | Immunotherapy | 3 | 2025 | 671 | 0.190 |
Why?
| | Cell Proliferation | 5 | 2021 | 2502 | 0.190 |
Why?
| | Liver | 3 | 2020 | 1864 | 0.190 |
Why?
| | Disease Models, Animal | 5 | 2020 | 4580 | 0.190 |
Why?
| | Pharmaceutical Preparations | 1 | 2005 | 172 | 0.190 |
Why?
| | Age Factors | 9 | 2021 | 3347 | 0.190 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2023 | 69 | 0.190 |
Why?
| | Aurora Kinase A | 2 | 2019 | 57 | 0.180 |
Why?
| | Women's Health | 1 | 2024 | 317 | 0.180 |
Why?
| | Chromatography, Liquid | 1 | 2004 | 453 | 0.180 |
Why?
| | Pilonidal Sinus | 1 | 2001 | 4 | 0.180 |
Why?
| | Condylomata Acuminata | 1 | 2001 | 7 | 0.180 |
Why?
| | Genomic Instability | 1 | 2022 | 64 | 0.180 |
Why?
| | Antineoplastic Agents, Immunological | 3 | 2019 | 200 | 0.180 |
Why?
| | Retrospective Studies | 11 | 2026 | 17438 | 0.170 |
Why?
| | Drug Monitoring | 2 | 2019 | 399 | 0.170 |
Why?
| | Proteomics | 2 | 2020 | 1203 | 0.170 |
Why?
| | Hematopoiesis | 1 | 2022 | 195 | 0.170 |
Why?
| | Nausea | 2 | 2018 | 111 | 0.170 |
Why?
| | Piperazines | 1 | 2023 | 368 | 0.170 |
Why?
| | Artificial Intelligence | 1 | 2026 | 389 | 0.170 |
Why?
| | Aged, 80 and over | 7 | 2025 | 8391 | 0.160 |
Why?
| | Genetic Testing | 3 | 2026 | 492 | 0.160 |
Why?
| | Ki-67 Antigen | 2 | 2019 | 120 | 0.160 |
Why?
| | Mass Spectrometry | 1 | 2004 | 729 | 0.160 |
Why?
| | Dyspareunia | 1 | 2020 | 8 | 0.160 |
Why?
| | Mice, Inbred BALB C | 6 | 2019 | 1244 | 0.160 |
Why?
| | Body Image | 3 | 2020 | 96 | 0.160 |
Why?
| | Cancer Care Facilities | 1 | 2020 | 48 | 0.160 |
Why?
| | Biopsy | 4 | 2018 | 1075 | 0.150 |
Why?
| | Pregnancy-Associated Plasma Protein-A | 1 | 2020 | 14 | 0.150 |
Why?
| | Ibuprofen | 2 | 2018 | 87 | 0.150 |
Why?
| | Risk | 3 | 2013 | 920 | 0.150 |
Why?
| | Neoplasm Grading | 5 | 2021 | 313 | 0.150 |
Why?
| | Mice, Inbred NOD | 1 | 2021 | 598 | 0.150 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 1195 | 0.150 |
Why?
| | Benzodiazepines | 1 | 2021 | 158 | 0.150 |
Why?
| | p21-Activated Kinases | 1 | 2019 | 13 | 0.150 |
Why?
| | Bone Neoplasms | 2 | 2016 | 272 | 0.150 |
Why?
| | Sexual Health | 1 | 2020 | 67 | 0.150 |
Why?
| | Cell Adhesion | 1 | 2020 | 447 | 0.140 |
Why?
| | Fatigue | 2 | 2018 | 363 | 0.140 |
Why?
| | Pregnancy Outcome | 4 | 2026 | 503 | 0.140 |
Why?
| | Immunohistochemistry | 8 | 2019 | 1712 | 0.140 |
Why?
| | Parkinson Disease | 2 | 2015 | 614 | 0.140 |
Why?
| | Sexual Dysfunctions, Psychological | 1 | 2019 | 29 | 0.140 |
Why?
| | Carcinoma, Ductal | 2 | 2011 | 10 | 0.140 |
Why?
| | Receptor, trkB | 1 | 2019 | 39 | 0.140 |
Why?
| | Germ Cells | 3 | 2024 | 67 | 0.140 |
Why?
| | Lymphangiogenesis | 2 | 2018 | 28 | 0.140 |
Why?
| | Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 21 | 0.140 |
Why?
| | Cell Communication | 1 | 2020 | 327 | 0.140 |
Why?
| | Pyrazoles | 3 | 2018 | 517 | 0.140 |
Why?
| | Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2018 | 14 | 0.140 |
Why?
| | Stress, Psychological | 2 | 2025 | 1171 | 0.140 |
Why?
| | Tryptophan Oxygenase | 1 | 2018 | 33 | 0.140 |
Why?
| | Ipilimumab | 1 | 2018 | 44 | 0.140 |
Why?
| | Neoplasm Proteins | 2 | 2020 | 444 | 0.140 |
Why?
| | Progesterone | 2 | 2025 | 214 | 0.140 |
Why?
| | Sexual Dysfunction, Physiological | 1 | 2019 | 74 | 0.130 |
Why?
| | Parenting | 1 | 2022 | 309 | 0.130 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2019 | 155 | 0.130 |
Why?
| | Cisplatin | 1 | 2020 | 347 | 0.130 |
Why?
| | Vitamin D | 1 | 2021 | 402 | 0.130 |
Why?
| | Area Under Curve | 1 | 2018 | 335 | 0.130 |
Why?
| | Cross-Sectional Studies | 7 | 2025 | 5899 | 0.130 |
Why?
| | Tretinoin | 1 | 2018 | 115 | 0.130 |
Why?
| | United States | 8 | 2025 | 16136 | 0.130 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2023 | 677 | 0.130 |
Why?
| | Immunity, Mucosal | 1 | 2018 | 97 | 0.130 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2018 | 415 | 0.130 |
Why?
| | Patient Care Management | 1 | 2017 | 54 | 0.130 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2019 | 268 | 0.120 |
Why?
| | Tryptophan | 1 | 2018 | 184 | 0.120 |
Why?
| | Granulocytes | 1 | 2017 | 82 | 0.120 |
Why?
| | Socioeconomic Factors | 5 | 2021 | 1327 | 0.120 |
Why?
| | Case-Control Studies | 3 | 2020 | 3647 | 0.120 |
Why?
| | Drug Delivery Systems | 2 | 2010 | 377 | 0.120 |
Why?
| | Global Health | 1 | 2020 | 403 | 0.120 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2001 | 628 | 0.120 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2019 | 429 | 0.120 |
Why?
| | Metaplasia | 1 | 2016 | 54 | 0.120 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2015 | 314 | 0.120 |
Why?
| | Pancreatic Cyst | 1 | 2017 | 50 | 0.120 |
Why?
| | Surveys and Questionnaires | 8 | 2024 | 6073 | 0.120 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2016 | 40 | 0.120 |
Why?
| | Prostatic Neoplasms | 2 | 2021 | 972 | 0.120 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2016 | 100 | 0.120 |
Why?
| | Dyskinesia, Drug-Induced | 1 | 1995 | 14 | 0.120 |
Why?
| | Cellular Microenvironment | 1 | 2016 | 94 | 0.110 |
Why?
| | Epithelium | 2 | 2015 | 295 | 0.110 |
Why?
| | Levodopa | 1 | 1995 | 40 | 0.110 |
Why?
| | Antiparkinson Agents | 1 | 1995 | 41 | 0.110 |
Why?
| | Cytophagocytosis | 1 | 2015 | 5 | 0.110 |
Why?
| | Prophylactic Surgical Procedures | 1 | 2015 | 7 | 0.110 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 344 | 0.110 |
Why?
| | Adherens Junctions | 1 | 2015 | 24 | 0.110 |
Why?
| | Transforming Growth Factor beta3 | 1 | 2015 | 15 | 0.110 |
Why?
| | Depression | 3 | 2020 | 1575 | 0.110 |
Why?
| | Lung Neoplasms | 2 | 2021 | 2675 | 0.110 |
Why?
| | Phosphoproteins | 2 | 2015 | 320 | 0.110 |
Why?
| | Paracrine Communication | 1 | 2015 | 67 | 0.110 |
Why?
| | Rats | 6 | 2021 | 5586 | 0.110 |
Why?
| | Menarche | 1 | 2015 | 53 | 0.110 |
Why?
| | Lymphocyte Activation | 3 | 2017 | 1137 | 0.110 |
Why?
| | Chronic Pain | 1 | 2019 | 304 | 0.110 |
Why?
| | Risk Reduction Behavior | 1 | 2016 | 220 | 0.110 |
Why?
| | Spleen | 1 | 2017 | 503 | 0.110 |
Why?
| | Lymph Node Excision | 2 | 2021 | 174 | 0.110 |
Why?
| | Microfilament Proteins | 1 | 2015 | 136 | 0.110 |
Why?
| | Hodgkin Disease | 1 | 2016 | 173 | 0.110 |
Why?
| | Pyrimidines | 1 | 2018 | 532 | 0.110 |
Why?
| | Survival Analysis | 4 | 2021 | 1378 | 0.100 |
Why?
| | Gastrointestinal Microbiome | 1 | 2022 | 769 | 0.100 |
Why?
| | Peptide YY | 2 | 2025 | 28 | 0.100 |
Why?
| | Survivors | 3 | 2023 | 526 | 0.100 |
Why?
| | Aging | 1 | 2025 | 1996 | 0.100 |
Why?
| | Odds Ratio | 4 | 2020 | 1077 | 0.100 |
Why?
| | Extracellular Matrix | 2 | 2016 | 565 | 0.100 |
Why?
| | Mammary Neoplasms, Animal | 1 | 2014 | 35 | 0.100 |
Why?
| | Amenorrhea | 1 | 2014 | 35 | 0.100 |
Why?
| | Carbon Cycle | 1 | 2014 | 13 | 0.100 |
Why?
| | Ghrelin | 2 | 2025 | 42 | 0.100 |
Why?
| | Administration, Oral | 3 | 2025 | 872 | 0.100 |
Why?
| | Calcium-Binding Proteins | 1 | 2015 | 221 | 0.100 |
Why?
| | Multivariate Analysis | 2 | 2019 | 1543 | 0.100 |
Why?
| | Brain Edema | 1 | 2014 | 63 | 0.100 |
Why?
| | Monocytes | 1 | 2017 | 538 | 0.100 |
Why?
| | Droughts | 1 | 2014 | 32 | 0.100 |
Why?
| | Disability Evaluation | 1 | 2015 | 297 | 0.100 |
Why?
| | Collagen | 2 | 2021 | 460 | 0.100 |
Why?
| | Atmosphere | 1 | 2014 | 52 | 0.100 |
Why?
| | Spouses | 1 | 2015 | 107 | 0.100 |
Why?
| | Tremor | 1 | 1994 | 98 | 0.100 |
Why?
| | Astrocytes | 1 | 2015 | 229 | 0.100 |
Why?
| | Male | 20 | 2022 | 73396 | 0.100 |
Why?
| | Neoplastic Cells, Circulating | 2 | 2016 | 81 | 0.100 |
Why?
| | Signal Transduction | 4 | 2020 | 5246 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 974 | 0.100 |
Why?
| | Trans-Activators | 1 | 2015 | 372 | 0.100 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 3 | 2019 | 66 | 0.090 |
Why?
| | Nitriles | 1 | 2014 | 212 | 0.090 |
Why?
| | Infertility, Female | 1 | 2014 | 124 | 0.090 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2012 | 27 | 0.090 |
Why?
| | Lymphatic Vessels | 3 | 2019 | 64 | 0.090 |
Why?
| | Triazoles | 1 | 2014 | 190 | 0.090 |
Why?
| | Postural Balance | 1 | 2015 | 249 | 0.090 |
Why?
| | Myeloid Cells | 1 | 2013 | 149 | 0.090 |
Why?
| | Apoptosis | 3 | 2019 | 2439 | 0.090 |
Why?
| | Drug Design | 1 | 2013 | 180 | 0.090 |
Why?
| | Logistic Models | 5 | 2016 | 2126 | 0.090 |
Why?
| | Genes, Bacterial | 1 | 2012 | 151 | 0.090 |
Why?
| | Genome-Wide Association Study | 1 | 2019 | 1537 | 0.090 |
Why?
| | Cardiovascular Diseases | 1 | 2024 | 2219 | 0.090 |
Why?
| | Live Birth | 2 | 2023 | 81 | 0.090 |
Why?
| | Interpersonal Relations | 1 | 2015 | 387 | 0.090 |
Why?
| | Analgesics, Opioid | 1 | 2021 | 1221 | 0.090 |
Why?
| | Fibrillar Collagens | 1 | 2011 | 15 | 0.090 |
Why?
| | Wound Healing | 1 | 2014 | 354 | 0.090 |
Why?
| | Mice, Inbred C57BL | 6 | 2019 | 6034 | 0.090 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 334 | 0.080 |
Why?
| | Double-Blind Method | 3 | 2021 | 2070 | 0.080 |
Why?
| | Membrane Proteins | 2 | 2015 | 1130 | 0.080 |
Why?
| | Patient Participation | 1 | 2015 | 457 | 0.080 |
Why?
| | Transcriptome | 2 | 2021 | 1068 | 0.080 |
Why?
| | Antigen Presentation | 2 | 2018 | 209 | 0.080 |
Why?
| | B7-H1 Antigen | 2 | 2026 | 245 | 0.080 |
Why?
| | Biopsy, Needle | 1 | 2011 | 183 | 0.080 |
Why?
| | Streptococcus agalactiae | 1 | 2012 | 118 | 0.080 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2020 | 930 | 0.080 |
Why?
| | Estrogen Antagonists | 1 | 2010 | 37 | 0.080 |
Why?
| | Sexual Behavior | 1 | 2014 | 490 | 0.080 |
Why?
| | Adenocarcinoma | 2 | 2015 | 927 | 0.080 |
Why?
| | Cell Fusion | 2 | 2006 | 47 | 0.070 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2021 | 222 | 0.070 |
Why?
| | Pregnancy Trimester, Second | 1 | 2009 | 91 | 0.070 |
Why?
| | Clinical Trials as Topic | 3 | 2017 | 1064 | 0.070 |
Why?
| | Sentinel Lymph Node Biopsy | 3 | 2021 | 118 | 0.070 |
Why?
| | Reference Standards | 2 | 2012 | 176 | 0.070 |
Why?
| | Cell Movement | 3 | 2019 | 951 | 0.070 |
Why?
| | Glatiramer Acetate | 1 | 2008 | 11 | 0.070 |
Why?
| | Interferon beta-1a | 1 | 2008 | 12 | 0.070 |
Why?
| | Mucin-1 | 1 | 2009 | 29 | 0.070 |
Why?
| | Pregnancy Trimester, First | 1 | 2009 | 140 | 0.070 |
Why?
| | Macrophage Activation | 1 | 2010 | 182 | 0.070 |
Why?
| | In Situ Hybridization, Fluorescence | 3 | 2019 | 334 | 0.070 |
Why?
| | Clinical Trials, Phase I as Topic | 2 | 2020 | 49 | 0.070 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2009 | 186 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2018 | 2022 | 0.070 |
Why?
| | Rats, Sprague-Dawley | 4 | 2016 | 2537 | 0.070 |
Why?
| | Metalloproteases | 1 | 2008 | 42 | 0.070 |
Why?
| | Interferon-beta | 1 | 2008 | 90 | 0.070 |
Why?
| | Extracellular Matrix Proteins | 1 | 2009 | 156 | 0.070 |
Why?
| | Sensitivity and Specificity | 3 | 2013 | 1998 | 0.070 |
Why?
| | Gonadal Steroid Hormones | 1 | 2009 | 143 | 0.070 |
Why?
| | Paclitaxel | 2 | 2026 | 260 | 0.070 |
Why?
| | Phenotype | 3 | 2026 | 3206 | 0.070 |
Why?
| | Age of Onset | 2 | 2021 | 558 | 0.060 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2009 | 372 | 0.060 |
Why?
| | Cell Cycle | 2 | 2021 | 595 | 0.060 |
Why?
| | Disease Susceptibility | 1 | 2009 | 339 | 0.060 |
Why?
| | Genomics | 2 | 2023 | 853 | 0.060 |
Why?
| | Maximum Tolerated Dose | 2 | 2018 | 217 | 0.060 |
Why?
| | Gene Knockdown Techniques | 2 | 2020 | 335 | 0.060 |
Why?
| | ErbB Receptors | 3 | 2017 | 636 | 0.060 |
Why?
| | Bridged-Ring Compounds | 1 | 2026 | 31 | 0.060 |
Why?
| | Mice, Nude | 3 | 2015 | 668 | 0.060 |
Why?
| | Sternum | 1 | 2006 | 26 | 0.060 |
Why?
| | Antibodies, Monoclonal | 3 | 2009 | 1512 | 0.060 |
Why?
| | Cell Survival | 2 | 2020 | 1105 | 0.060 |
Why?
| | Cells, Cultured | 3 | 2019 | 4118 | 0.060 |
Why?
| | Taxoids | 1 | 2026 | 115 | 0.060 |
Why?
| | Polymerase Chain Reaction | 2 | 2016 | 1031 | 0.060 |
Why?
| | Risk Assessment | 3 | 2026 | 3712 | 0.060 |
Why?
| | Membrane Glycoproteins | 2 | 2019 | 495 | 0.060 |
Why?
| | Ovariectomy | 2 | 2019 | 164 | 0.060 |
Why?
| | Keratins | 1 | 2026 | 57 | 0.060 |
Why?
| | Postmenopause | 2 | 2005 | 394 | 0.060 |
Why?
| | HIV Infections | 1 | 2001 | 3215 | 0.060 |
Why?
| | Axilla | 2 | 2021 | 51 | 0.060 |
Why?
| | Parturition | 1 | 2026 | 72 | 0.060 |
Why?
| | Child | 6 | 2022 | 22693 | 0.060 |
Why?
| | Models, Biological | 2 | 2012 | 1761 | 0.060 |
Why?
| | Forkhead Transcription Factors | 2 | 2018 | 209 | 0.060 |
Why?
| | Prolactin | 1 | 2025 | 88 | 0.060 |
Why?
| | Mammaplasty | 2 | 2021 | 150 | 0.050 |
Why?
| | Fear | 2 | 2021 | 373 | 0.050 |
Why?
| | Anti-Mullerian Hormone | 1 | 2025 | 62 | 0.050 |
Why?
| | Mice, Knockout | 2 | 2025 | 3125 | 0.050 |
Why?
| | Thyrotropin | 1 | 2025 | 120 | 0.050 |
Why?
| | PTEN Phosphohydrolase | 1 | 2026 | 166 | 0.050 |
Why?
| | Infant, Newborn | 2 | 2023 | 6460 | 0.050 |
Why?
| | Dendritic Cells | 2 | 2005 | 509 | 0.050 |
Why?
| | Analysis of Variance | 3 | 2014 | 1298 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2008 | 823 | 0.050 |
Why?
| | Solubility | 1 | 2005 | 240 | 0.050 |
Why?
| | Congresses as Topic | 1 | 2026 | 226 | 0.050 |
Why?
| | Neoplastic Processes | 1 | 2023 | 5 | 0.050 |
Why?
| | Ovulation Induction | 1 | 2024 | 68 | 0.050 |
Why?
| | Cancer Vaccines | 1 | 2005 | 161 | 0.050 |
Why?
| | Follicle Stimulating Hormone | 1 | 2025 | 265 | 0.050 |
Why?
| | Weaning | 2 | 2016 | 50 | 0.050 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2025 | 219 | 0.050 |
Why?
| | North America | 1 | 2024 | 300 | 0.050 |
Why?
| | Celecoxib | 2 | 2014 | 41 | 0.050 |
Why?
| | Cryopreservation | 1 | 2024 | 115 | 0.050 |
Why?
| | Withholding Treatment | 1 | 2023 | 77 | 0.050 |
Why?
| | Sensation | 1 | 2022 | 56 | 0.050 |
Why?
| | Peptides | 1 | 2008 | 992 | 0.050 |
Why?
| | DNA End-Joining Repair | 1 | 2022 | 22 | 0.050 |
Why?
| | Mucins | 1 | 2022 | 75 | 0.040 |
Why?
| | Cost of Illness | 1 | 2024 | 323 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 330 | 0.040 |
Why?
| | Chromosome Aberrations | 1 | 2022 | 167 | 0.040 |
Why?
| | Colorado | 3 | 2020 | 4595 | 0.040 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2015 | 522 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2025 | 731 | 0.040 |
Why?
| | Genes, p53 | 1 | 2021 | 56 | 0.040 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2021 | 44 | 0.040 |
Why?
| | Multiple Myeloma | 1 | 2005 | 310 | 0.040 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2021 | 116 | 0.040 |
Why?
| | Hypertrophy | 1 | 2021 | 127 | 0.040 |
Why?
| | Placebos | 1 | 2021 | 192 | 0.040 |
Why?
| | In Situ Hybridization | 1 | 2001 | 317 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2012 | 3416 | 0.040 |
Why?
| | Protective Agents | 1 | 2021 | 43 | 0.040 |
Why?
| | Societies, Medical | 1 | 2025 | 907 | 0.040 |
Why?
| | Referral and Consultation | 1 | 2007 | 881 | 0.040 |
Why?
| | Immunity | 1 | 2021 | 141 | 0.040 |
Why?
| | Neoplasm, Residual | 1 | 2021 | 143 | 0.040 |
Why?
| | Hormones | 1 | 2021 | 134 | 0.040 |
Why?
| | DNA Replication | 1 | 2022 | 248 | 0.040 |
Why?
| | Hospitals, University | 1 | 2021 | 178 | 0.040 |
Why?
| | Arm | 1 | 2021 | 111 | 0.040 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2019 | 1150 | 0.040 |
Why?
| | Pregnancy Rate | 1 | 2020 | 83 | 0.040 |
Why?
| | Early Detection of Cancer | 1 | 2026 | 506 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2022 | 615 | 0.040 |
Why?
| | DNA Repair | 1 | 2022 | 255 | 0.040 |
Why?
| | Flow Cytometry | 3 | 2013 | 1163 | 0.040 |
Why?
| | Morbidity | 1 | 2021 | 319 | 0.040 |
Why?
| | Confidence Intervals | 1 | 2020 | 329 | 0.040 |
Why?
| | Consolidation Chemotherapy | 1 | 2019 | 11 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2021 | 417 | 0.040 |
Why?
| | Age Distribution | 1 | 2020 | 399 | 0.040 |
Why?
| | Kidney Neoplasms | 1 | 2004 | 419 | 0.040 |
Why?
| | SEER Program | 1 | 2021 | 233 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 516 | 0.040 |
Why?
| | DNA, Viral | 1 | 2001 | 354 | 0.040 |
Why?
| | Base Sequence | 2 | 2016 | 2123 | 0.040 |
Why?
| | Vaginal Diseases | 1 | 2019 | 19 | 0.040 |
Why?
| | Fibronectins | 1 | 2020 | 136 | 0.040 |
Why?
| | Unemployment | 1 | 2019 | 43 | 0.040 |
Why?
| | Severity of Illness Index | 2 | 2019 | 2921 | 0.040 |
Why?
| | Leuprolide | 1 | 2019 | 21 | 0.040 |
Why?
| | Terminology as Topic | 1 | 2021 | 253 | 0.040 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2019 | 61 | 0.040 |
Why?
| | Sulfonamides | 2 | 2014 | 594 | 0.040 |
Why?
| | Interleukin-10 | 2 | 2014 | 310 | 0.030 |
Why?
| | Crosses, Genetic | 1 | 2018 | 120 | 0.030 |
Why?
| | Weight Gain | 1 | 2022 | 562 | 0.030 |
Why?
| | Hot Flashes | 1 | 2019 | 92 | 0.030 |
Why?
| | Maintenance Chemotherapy | 1 | 2018 | 41 | 0.030 |
Why?
| | Factor Analysis, Statistical | 1 | 2019 | 298 | 0.030 |
Why?
| | Integrins | 1 | 2018 | 88 | 0.030 |
Why?
| | Body Weight | 1 | 2022 | 968 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2019 | 157 | 0.030 |
Why?
| | Kynurenine | 1 | 2018 | 114 | 0.030 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2018 | 108 | 0.030 |
Why?
| | Contraceptives, Oral | 1 | 2017 | 37 | 0.030 |
Why?
| | Behavior | 1 | 2018 | 90 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2020 | 633 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2021 | 706 | 0.030 |
Why?
| | Dietary Supplements | 1 | 2021 | 587 | 0.030 |
Why?
| | Educational Status | 1 | 2019 | 466 | 0.030 |
Why?
| | Tumor Escape | 1 | 2017 | 50 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2019 | 1036 | 0.030 |
Why?
| | Weight Loss | 1 | 2022 | 858 | 0.030 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2016 | 56 | 0.030 |
Why?
| | Cell Count | 1 | 2017 | 315 | 0.030 |
Why?
| | Emulsions | 1 | 2016 | 58 | 0.030 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2024 | 892 | 0.030 |
Why?
| | Alleles | 1 | 2019 | 907 | 0.030 |
Why?
| | Population Surveillance | 1 | 2019 | 481 | 0.030 |
Why?
| | Immune Tolerance | 1 | 2018 | 386 | 0.030 |
Why?
| | Radiotherapy Dosage | 1 | 2016 | 289 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2017 | 324 | 0.030 |
Why?
| | Antigens, Differentiation | 1 | 2015 | 75 | 0.030 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2016 | 150 | 0.030 |
Why?
| | Body Mass Index | 2 | 2015 | 2458 | 0.030 |
Why?
| | Directive Counseling | 1 | 2015 | 48 | 0.030 |
Why?
| | Hybrid Cells | 2 | 2005 | 47 | 0.030 |
Why?
| | Reproduction | 1 | 2016 | 209 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2018 | 447 | 0.030 |
Why?
| | Biomarkers | 2 | 2021 | 4340 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1763 | 0.030 |
Why?
| | Medication Adherence | 1 | 2019 | 535 | 0.030 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2015 | 80 | 0.030 |
Why?
| | Medicare | 1 | 2021 | 920 | 0.030 |
Why?
| | Posture | 1 | 2015 | 182 | 0.030 |
Why?
| | Tropical Climate | 1 | 2014 | 13 | 0.030 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 266 | 0.030 |
Why?
| | Genotype | 1 | 2019 | 1879 | 0.030 |
Why?
| | Biota | 1 | 2014 | 28 | 0.030 |
Why?
| | Cognition | 1 | 2022 | 1292 | 0.030 |
Why?
| | Leukocyte Common Antigens | 1 | 2014 | 86 | 0.030 |
Why?
| | Dinoprostone | 1 | 2014 | 179 | 0.030 |
Why?
| | Trees | 1 | 2014 | 61 | 0.020 |
Why?
| | Fresh Water | 1 | 2014 | 53 | 0.020 |
Why?
| | STAT5 Transcription Factor | 1 | 2013 | 51 | 0.020 |
Why?
| | Tumor Burden | 1 | 2015 | 326 | 0.020 |
Why?
| | Rain | 1 | 2014 | 38 | 0.020 |
Why?
| | Terminal Care | 1 | 2018 | 284 | 0.020 |
Why?
| | Biomass | 1 | 2014 | 96 | 0.020 |
Why?
| | Blood Cell Count | 1 | 2013 | 56 | 0.020 |
Why?
| | Carbon Monoxide | 1 | 2014 | 82 | 0.020 |
Why?
| | Brazil | 1 | 2014 | 179 | 0.020 |
Why?
| | Dermoscopy | 1 | 2013 | 11 | 0.020 |
Why?
| | Immunoblotting | 1 | 2014 | 294 | 0.020 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 365 | 0.020 |
Why?
| | Massachusetts | 1 | 2014 | 178 | 0.020 |
Why?
| | Necrosis | 1 | 2014 | 243 | 0.020 |
Why?
| | Family Health | 1 | 1994 | 194 | 0.020 |
Why?
| | Oncogenes | 1 | 2013 | 113 | 0.020 |
Why?
| | Wnt Signaling Pathway | 1 | 2015 | 211 | 0.020 |
Why?
| | Fires | 1 | 2014 | 76 | 0.020 |
Why?
| | beta Catenin | 1 | 2015 | 250 | 0.020 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2013 | 88 | 0.020 |
Why?
| | Photosynthesis | 1 | 2014 | 104 | 0.020 |
Why?
| | Child, Preschool | 2 | 2021 | 11913 | 0.020 |
Why?
| | Karyotyping | 1 | 2012 | 106 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2025 | 3926 | 0.020 |
Why?
| | Immune System | 1 | 2014 | 181 | 0.020 |
Why?
| | Adiposity | 1 | 2017 | 533 | 0.020 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2014 | 215 | 0.020 |
Why?
| | Accidental Falls | 1 | 2015 | 227 | 0.020 |
Why?
| | Observer Variation | 1 | 2013 | 356 | 0.020 |
Why?
| | Endothelial Cells | 1 | 2018 | 876 | 0.020 |
Why?
| | Cell Division | 1 | 2013 | 736 | 0.020 |
Why?
| | Opioid-Related Disorders | 1 | 2021 | 634 | 0.020 |
Why?
| | Carbon Dioxide | 1 | 2014 | 228 | 0.020 |
Why?
| | Comorbidity | 1 | 2017 | 1665 | 0.020 |
Why?
| | Menopause | 1 | 2015 | 328 | 0.020 |
Why?
| | Carcinogenesis | 1 | 2013 | 226 | 0.020 |
Why?
| | Calibration | 1 | 2012 | 154 | 0.020 |
Why?
| | Recurrence | 1 | 2015 | 1133 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2019 | 2240 | 0.020 |
Why?
| | Interferon-gamma | 2 | 2005 | 781 | 0.020 |
Why?
| | Seasons | 1 | 2014 | 540 | 0.020 |
Why?
| | RNA, Bacterial | 1 | 2012 | 183 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 2 | 2015 | 2786 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2018 | 1982 | 0.020 |
Why?
| | Cell Line | 1 | 2016 | 2814 | 0.020 |
Why?
| | Mice, SCID | 1 | 2011 | 360 | 0.020 |
Why?
| | Genome, Human | 1 | 2013 | 431 | 0.020 |
Why?
| | Photochemotherapy | 1 | 2010 | 39 | 0.020 |
Why?
| | Self Report | 1 | 2015 | 870 | 0.020 |
Why?
| | Universities | 1 | 2013 | 451 | 0.020 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2012 | 340 | 0.020 |
Why?
| | Hypertension | 1 | 2018 | 1272 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2010 | 322 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2014 | 1135 | 0.020 |
Why?
| | Matrix Metalloproteinases | 1 | 2010 | 95 | 0.020 |
Why?
| | Survival Rate | 1 | 2014 | 2092 | 0.020 |
Why?
| | Keratin-19 | 1 | 2009 | 4 | 0.020 |
Why?
| | Immunomagnetic Separation | 1 | 2009 | 4 | 0.020 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 2009 | 21 | 0.020 |
Why?
| | Palliative Care | 1 | 2018 | 1032 | 0.020 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2009 | 77 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2013 | 1503 | 0.020 |
Why?
| | Blotting, Western | 1 | 2011 | 1177 | 0.020 |
Why?
| | Vinblastine | 1 | 2009 | 75 | 0.020 |
Why?
| | Physician-Patient Relations | 1 | 2014 | 597 | 0.020 |
Why?
| | Species Specificity | 1 | 2010 | 543 | 0.020 |
Why?
| | ADAM12 Protein | 1 | 2008 | 4 | 0.020 |
Why?
| | Flavonoids | 1 | 2009 | 85 | 0.020 |
Why?
| | Estrogen Receptor Modulators | 1 | 2008 | 14 | 0.020 |
Why?
| | Perilipin-1 | 1 | 2008 | 16 | 0.020 |
Why?
| | S100 Proteins | 1 | 2008 | 33 | 0.020 |
Why?
| | Sex Factors | 1 | 1994 | 2107 | 0.020 |
Why?
| | ADAM Proteins | 1 | 2008 | 65 | 0.020 |
Why?
| | Androstadienes | 1 | 2008 | 77 | 0.020 |
Why?
| | Perimenopause | 1 | 2008 | 69 | 0.020 |
Why?
| | DNA Primers | 1 | 2009 | 487 | 0.020 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2009 | 139 | 0.020 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2008 | 128 | 0.020 |
Why?
| | Radiotherapy | 1 | 2008 | 209 | 0.020 |
Why?
| | Prevalence | 1 | 2014 | 2861 | 0.020 |
Why?
| | Gene Expression | 1 | 2012 | 1463 | 0.020 |
Why?
| | Piperidines | 1 | 2009 | 225 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 517 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2008 | 496 | 0.020 |
Why?
| | Precancerous Conditions | 1 | 2008 | 162 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2009 | 834 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2008 | 752 | 0.010 |
Why?
| | Pleural Effusion | 1 | 2006 | 59 | 0.010 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2005 | 49 | 0.010 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2005 | 39 | 0.010 |
Why?
| | Receptors, CCR7 | 1 | 2005 | 32 | 0.010 |
Why?
| | Receptors, Chemokine | 1 | 2005 | 47 | 0.010 |
Why?
| | Antigens, CD34 | 1 | 2005 | 89 | 0.010 |
Why?
| | Interleukin-12 | 1 | 2005 | 115 | 0.010 |
Why?
| | Hemocyanins | 1 | 2004 | 61 | 0.010 |
Why?
| | Positron-Emission Tomography | 1 | 2006 | 343 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2008 | 728 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2004 | 245 | 0.010 |
Why?
| | Patient Care Planning | 1 | 2005 | 170 | 0.010 |
Why?
| | Cell Separation | 1 | 2004 | 300 | 0.010 |
Why?
| | Cell Nucleus | 1 | 2006 | 584 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2004 | 882 | 0.010 |
Why?
| | Brain | 1 | 2014 | 2991 | 0.010 |
Why?
| | Pilot Projects | 1 | 2003 | 1888 | 0.010 |
Why?
| | Vaccination | 1 | 2004 | 1449 | 0.010 |
Why?
|
|
Borges's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|